Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. 1981

G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006413 Hematopoietic System The blood-making organs and tissues, principally the bone marrow and lymph nodes. Hematopoietic Systems,System, Hematopoietic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716

Related Publications

G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
March 2003, Cancer chemotherapy and pharmacology,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
April 1997, Anti-cancer drugs,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
November 2006, Blood,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
September 1986, Cancer research,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
January 2013, Cancer chemotherapy and pharmacology,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
May 2006, Cancer research,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
December 1989, Bone marrow transplantation,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
March 2005, Anti-cancer drugs,
G E Rivard, and R L Momparler, and J Demers, and P Benoit, and R Raymond, and K Lin, and L F Momparler
July 2005, Seminars in hematology,
Copied contents to your clipboard!